Novo Nordisk Korea has applied to the Health Insurance Review and Assessment Service for reimbursement of its obesity drug Wegovy, pharmaceutical industry sources said Tuesday. This move aims to significantly lower treatment costs and intensify competition in Korea's obesity drug market, where it seeks to regain ground against Eli Lilly's market-leading Mounjaro and Hanmi Pharmaceutical's upcoming homegrown rival, Eppe.